Blockchain Registration Transaction Record

NanoViricides Advances NV-387 Toward Phase II for MPox

NanoViricides announces quarterly report, advancing NV-387 to Phase II for MPox in DRC. FDA orphan drug designation for measles obtained. Broad-spectrum antiviral pipeline progresses. Read more.

This news matters because it highlights progress in developing broad-spectrum antiviral treatments that could address multiple viral diseases, including MPox and measles. If successful, NV-387 could provide a much-needed therapy for populations in regions like the Democratic Republic of Congo, where MPox is endemic, and for other viral outbreaks. The orphan drug designation for measles also underscores the potential to treat a neglected disease that still causes significant morbidity worldwide. For investors, the company's regulatory advancements signal potential growth and validation of its nanomedicine platform.